» Articles » PMID: 29930763

Extensive Screening of MicroRNA Populations Identifies Hsa-miR-375 and Hsa-miR-133a-3p As Selective Markers for Human Rectal and Colon Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Jun 23
PMID 29930763
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are ∼22-nt molecules exerting control of protein expression in cancer tissues. The current study determined the full spectrum of miRNA dysregulation in freshly isolated human colon or rectal cancer biopsies as well as in controls of healthy adjacent tissue (total of = 100) using an Illumina sequencing technology. In this work, we aimed to identify miRNAs that may serve as future marker to discern between these two subtypes. DESeq2 analysis revealed 53 significantly dysregulated miRNAs in colon cancer, 67 miRNAs in rectal cancer, and 97 miRNAs in both at a value < 0.05 and ≥ 10 read counts. 65% of miRNAs were upregulated in colon as well as rectal cancer. Highest significant dysregulation ( < 0.00001) was detected for hsa-miR-21-5p, -215-5p and -378a in both colon and rectal cancer. Among the group of miRNAs with < 0.05 and more than 2-fold expression differences, hsa-miR-375 was detected in rectal cancer only, and hsa-miR-133a-3p only in colon cancer. Receiver operating characteristic (ROC) analysis confirmed highly distinct sensitivities for hsa-miR-375 to detect rectal cancer (area under the curve (AUC): 0.9), while hsa-miR-133a-3p (AUC: 0.89) had the highest sensitivity for detecting colon cancer. We conclude that hsa-miR-375 and hsa-miR-133a-3p may serve as new markers of rectal or colon cancer and should be further investigated to search for different etiologies of colorectal cancer.

Citing Articles

Identification and evaluation of a serum microRNA panel to diagnose colorectal cancer patients.

Ng L, Sin R, Cheung D, Wong C, Lam C, Leung W Int J Cancer. 2024; 156(4):865-874.

PMID: 39244686 PMC: 11661512. DOI: 10.1002/ijc.35175.


Exploring ceRNA networks for key biomarkers in breast cancer subtypes and immune regulation.

Shariatmadar Taleghani A, Beigi Y, Zare-Mirakabad F, Masoudi-Nejad A Sci Rep. 2023; 13(1):20795.

PMID: 38012271 PMC: 10682442. DOI: 10.1038/s41598-023-47816-z.


A novel long noncoding RNA AC125257.1 facilitates colorectal cancer progression by targeting miR-133a-3p/CASC5 axis.

Liao C, Zheng Z, Liu J, Li J, Li R, Hu S Open Med (Wars). 2023; 18(1):20230631.

PMID: 37009050 PMC: 10052384. DOI: 10.1515/med-2023-0631.


Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma.

Prinz C, Frese R, Grams M, Fehring L Genes (Basel). 2022; 13(8).

PMID: 36011390 PMC: 9407895. DOI: 10.3390/genes13081479.


MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions.

Prinz C, Fehring L, Frese R Cells. 2022; 11(15).

PMID: 35954223 PMC: 9368175. DOI: 10.3390/cells11152374.


References
1.
Riihimaki M, Hemminki A, Sundquist J, Hemminki K . Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016; 6:29765. PMC: 4945942. DOI: 10.1038/srep29765. View

2.
Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

3.
Xu L, Li M, Wang M, Yan D, Feng G, An G . The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer. 2014; 14:714. PMC: 4181388. DOI: 10.1186/1471-2407-14-714. View

4.
Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

5.
Patel M, Verma A, Aslam I, Pringle H, Singh B . Novel plasma microRNA biomarkers for the identification of colitis-associated carcinoma. Lancet. 2015; 385 Suppl 1:S78. DOI: 10.1016/S0140-6736(15)60393-2. View